Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + golcadomide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Rituximab + golcadomide is a combination therapy being investigated for the treatment of various types of lymphoma, particularly follicular lymphoma. Golcadomide is a novel CELMoD (Cereblon E3 Ligase Modulator) agent that targets proteins called Ikaros and Aiolos to produce dual immunomodulatory and anti-tumor activity, with preferential distribution to lymphoid organs. Rituximab is a monoclonal antibody that targets CD20, a protein found on the surface of B cells. The combination has shown promising efficacy in clinical trials for both newly diagnosed and relapsed/refractory follicular lymphoma, with durable responses observed.
- Brand names
- golcadomide
- Other names
- Golca + RGOLCA + RTXgolcadomide plus rituximab
02
Targets
IKZF1 (Ikaros family zinc finger protein 1)CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on rituximab + golcadomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + golcadomide.